Compare WKHS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | APM |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 18.9M |
| IPO Year | N/A | 2018 |
| Metric | WKHS | APM |
|---|---|---|
| Price | $0.78 | $1.34 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.75 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 109.4K |
| Earning Date | 11-10-2025 | 12-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,620,296.00 | N/A |
| Revenue This Year | $92.70 | N/A |
| Revenue Next Year | $34.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.73 | N/A |
| 52 Week Low | $0.53 | $0.65 |
| 52 Week High | $15.75 | $7.49 |
| Indicator | WKHS | APM |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 43.44 |
| Support Level | $0.79 | $1.27 |
| Resistance Level | $0.90 | $1.38 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 45.67 | 21.57 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.